FDA Clearance Tracker · P140026-S016
ENROUTE Transcarotid Stent System
Last checked: Nov 20, 2026Latest source record: Apr 28, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Apr 28, 2022
Approved
Time to decision
429 days
Received Feb 23, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P140026-S016
- Device name
- ENROUTE Transcarotid Stent System
- Applicant
- Boston Scientific Corporation
- Applicant location
- Marborough, MA
- Received
- Feb 23, 2021
- Decided
- Apr 28, 2022
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P140026
Device type
- Device type
- Stent, carotid (NIM)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for the expansion of the Indications for Use to include treatment of patients at standard risk for adverse events from carotid endartectomy.
Source documents
Other decisions for Boston Scientific Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- SpaceOAR Flex System510(k)
K262151 · Decided Sep 11, 2026 · 78 days after receipt
Device type: Hydrogel Spacer (OVB) · Radiology & Imaging
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.